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The tendency of mitochondria to undergo or resist BCL2-controlled apoptosis (so-called mitochondrial priming) is a powerful 
predictor of response to cytotoxic chemotherapy. Fully exploiting this finding will require unraveling the molecular genetics 
underlying phenotypic variability in mitochondrial priming. Here, we report that mitochondrial apoptosis resistance in T cell 
acute lymphoblastic leukemia (T-ALL) is mediated by inactivation of polycomb repressive complex 2 (PRC2). In T-ALL clinical 
specimens, loss-of-function mutations of PRC2 core components (EZH2, EED, or SUZ12) were associated with mitochondrial 
apoptosis resistance. In T-ALL cells, PRC2 depletion induced resistance to apoptosis induction by multiple chemotherapeutics 
with distinct mechanisms of action. PRC2 loss induced apoptosis resistance via transcriptional up-regulation of the LIM 
domain transcription factor CRIP2 and downstream up-regulation of the mitochondrial chaperone TRAP1. These findings 
demonstrate the importance of mitochondrial apoptotic priming as a prognostic factor in T-ALL and implicate mitochondrial 
chaperone function as a molecular determinant of chemotherapy response.
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Introduction
Conventional combination chemotherapy remains the primary 
treatment modality with curative potential for most patients 
with metastatic cancer. Effective chemotherapy regimens typ-
ically combine drugs with distinct mechanisms of action to 
minimize emergence of resistance. Nevertheless, treatment re-
sponses are often highly variable among patients with clinically 
indistinguishable tumors. For example, while intensive combi-
nation chemotherapy cures a substantial fraction of T cell acute 
lymphoblastic leukemia (T-ALL), front-line therapy fails in 15–
25% of children and 40–50% of adults with the disease, and these 
patients have a very poor prognosis (Goldberg et al., 2003; Marks 
et al., 2009). Strikingly, chemotherapy resistance in T-ALL often 
manifests as induction failure (Goldberg et al., 2003; Oudot et 
al., 2008), in which the first cycle of intensive combination che-
motherapy fails to induce disease remission. Despite consider-
able insights into the molecular mechanisms underlying cellular 
transformation, the pathobiology of resistance to conventional 
chemotherapy remains poorly understood.
Decreased proliferation rate provides one mechanism for che-
motherapy resistance in some contexts. For example, culture of 
leukemic cells in nonproliferative conditions induces resistance 
to antimetabolites and vinca alkaloids (Schabel et al., 1965), and 
recent work has revealed that relapses can arise from rare hy-
poproliferative cells in ALL (Ebinger et al., 2016). However, sev-
eral drugs with a central role in contemporary T-ALL therapy, 
such as asparaginase, corticosteroids, and DNA-damaging agents, 
remain highly active against hypoproliferative leukemic cells 
(Schabel et al., 1965; Mauer, 1975). Additionally, some studies of 
*I.M. Ariës, K. Bodaar, S.A. Karim, and T. Ni Chonghaile contributed equally to this paper; Correspondence to Alejandro Gutierrez: alejandro.gutierrez@ childrens 
.harvard .edu. 
© 2018 Ariës et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http:// www .rupress .org/ terms/ ). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 
International license, as described at https:// creativecommons .org/ licenses/ by -nc -sa/ 4 .0/ ).
1Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA; 2Department of Medical Oncology, Dana-Farber Cancer 
Institute, Harvard Medical School, Boston, MA; 3Deparment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; 4Department 
of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 5Department of Pediatric Oncology, University Hospital Muenster, 
Muenster, Germany; 6Center for Medical Genetics, Ghent University, Ghent, Belgium; 7Cancer Research Institute Ghent (CRIG), Ghent, Belgium; 8Department of 
Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; 9Department of Biostatistics, University of Florida, Gainesville, FL; 10Department 
of Pediatrics, University of California San Francisco, San Francisco, CA; 11Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA; 12Division 
of Pediatric Hematology/Oncology, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX; 13Cancer and Blood Disorders Department, Children’s 
Minnesota, Minneapolis, MN; 14Department of Pediatrics, Carilion Children’s, Roanoke, VA; 15Department of Laboratory Medicine, University of Washington, Seattle, 
WA; 16Howard Hughes Medical Institute, Boston, MA.
on November 29, 2018jem.rupress.org Downloaded from 
http://doi.org/10.1084/jem.20180570Published Online: 7 November, 2018 | Supp Info: 
Ariës et al. 
PRC2 loss induces chemoresistance in T-ALL
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180570
2
proliferation rate in pretreatment ALL clinical specimens have 
suggested that chemotherapy resistance is associated with in-
creased, rather than decreased, proliferation (Scarffe et al., 1980; 
Dow et al., 1982). Thus, proliferation rate cannot fully explain 
primary chemotherapy resistance. Loss-of-function mutations 
of TP53 or CDNK2A have been shown to mediate chemotherapy 
resistance in model systems (Lowe et al., 1994; Schmitt et al., 
1999). However, TP53 mutations are very rare at T-ALL diagno-
sis (Hsiao et al., 1994), whereas CDKN2A deletions are common 
but lack a consistent association with treatment failure (Rubnitz 
et al., 1997; Ramakers-van Woerden et al., 2001; Gutierrez et al., 
2010). Drug resistance mutations are identified more commonly 
at relapse, including TP53 mutations and activating mutations of 
the NT5C2 nucleotidase that induce resistance to 6-mercaptopu-
rine (Hsiao et al., 1994; Meyer et al., 2013; Tzoneva et al., 2013), 
but these are very rare in treatment-naive patients, indicating 
selection under evolutionary pressure. Thus, the molecular ge-
netics underlying primary chemotherapy resistance in T-ALL 
remain poorly understood.
Pretreatment resistance to mitochondrial apoptosis is a cel-
lular phenotype that predicts resistance to cytotoxic chemo-
therapy in a range of human cancers (Ni Chonghaile et al., 2011; 
Vo et al., 2012; Bhola et al., 2016), findings that we extend here 
to T-ALL. However, the molecular mechanisms underlying the 
striking phenotypic variability in chemotherapy response among 
patients with seemingly identical tumors remain poorly under-
stood. Here, we show that loss-of-function mutations in any of 
three core components of polycomb repressive complex 2 (PRC2; 
EZH2, EED, or SUZ12) are associated with resistance to mitochon-
drial apoptosis. PRC2 depletion in human T-ALL cells induced 
resistance to mitochondrial apoptosis induction by multiple an-
tileukemic drugs with distinct mechanisms of action, including 
dexamethasone, doxorubicin, and vincristine. PRC2 inactivation 
led to transcriptional up-regulation of the LIM domain transcrip-
tion factor CRIP2 and downstream up-regulation of the TRAP1 
gene, which encodes a mitochondrial chaperone protein of the 
HSP90 family (Felts et al., 2000; Kang et al., 2007). Importantly, 
we found that TRAP1 overexpression was necessary for induction 
of chemotherapy resistance downstream of PRC2 inactivation, 
and pharmacologic inhibition of TRAP1 synergized with dexa-
methasone and doxorubicin. These findings demonstrate the 
prognostic importance of mitochondrial apoptotic priming in 
T-ALL and implicate mitochondrial chaperone function as a key 
determinant of chemotherapy response.
Results
Mitochondrial apoptosis resistance predicts primary 
chemotherapy resistance in T-ALL
To investigate mechanisms underlying phenotypic variability in 
chemotherapy response, we focused on childhood T-ALL because 
combination chemotherapy is often curative, but treatment re-
sistance commonly presents as failure of induction chemother-
apy (Goldberg et al., 2003; Oudot et al., 2008). Induction failure, 
in which the first cycle of intensive combination chemotherapy 
fails to induce disease remission, strongly suggests primary or 
preexisting chemotherapy resistance. To test whether mito-
chondrial apoptosis resistance predicts T-ALL treatment fail-
ure, we analyzed a cohort of T-ALL specimens collected before 
the initiation of therapy in children treated on contemporary 
clinical trials (Table S1). BH3 profiling was performed to assess 
mitochondrial apoptotic priming, based on the ability of a fixed 
dose of pro-apoptotic peptide encoding the active site of BIM 
(also known as BCL2L11) to trigger loss of mitochondrial mem-
brane potential (Ni Chonghaile et al., 2011). Resistance to mito-
chondrial apoptosis was associated with high levels of residual 
leukemia in the bone marrow at the end of this initial phase of 
chemotherapy (Fig. 1 A), based on the 10% cutoff that most ro-
bustly predicts outcome in a large cohort of childhood T-ALL 
(Wood et al., 2014). To assess whether mitochondrial apoptosis 
resistance predicts survival, we classified patients into apop-
tosis-sensitive or apoptosis-resistant groups based on whether 
they were above or below the median mitochondrial depolar-
ization by BH3 profiling. Mitochondrial apoptosis resistance 
predicted significantly inferior event-free survival (65% versus 
91% at 5 yr; P = 0.0376; Fig. 1 B), as well as a trend toward infe-
rior overall survival that did not reach statistical significance 
(78% versus 96% at 5 yr; P = 0.091; Fig. 1 C). No other clinical 
features were significant predictors of mitochondrial apoptosis 
resistance in this cohort (Table S2).
PRC2 mutations are associated with resistance to 
mitochondrial apoptosis in T-ALL
Our findings further strengthen the link between priming of 
the mitochondrial apoptotic machinery and chemotherapy re-
sponse in diverse human cancers (Ni Chonghaile et al., 2011; Vo 
et al., 2012), but the molecular genetics underlying phenotypic 
variability in mitochondrial priming remain poorly understood. 
To investigate underlying mechanisms, we began by applying 
targeted exome sequencing, array comparative genomic hy-
bridization (CGH), and RNA sequencing analysis (RNA-seq) to 
all cases with sufficient available material (Tables S1 and S3–S6) 
The best-known regulators of mitochondrial apoptosis are genes 
of the BCL2 family (Davids and Letai, 2012; Czabotar et al., 2014), 
but RNA-seq revealed no difference in expression of any of the 
known pro- or antiapoptotic BCL2 family genes between apopto-
sis-sensitive versus resistant primary patient samples (Fig. S1 A). 
Prior work has implicated mutations of TP53, CDKN2A, PTEN, 
NOT CH1, or FBW7 in chemotherapy response (Lowe et al., 1994; 
Schmitt et al., 1999; Gutierrez et al., 2009; Mansour et al., 2009), 
but none of these were associated with mitochondrial apoptotic 
priming in this cohort (Fig. S1 B).
Resistance to mitochondrial apoptosis was associated with de-
letions or mutations of EZH2, EED, or SUZ12, which encode core 
components of PRC2. In the 40 T-ALL samples analyzed by both 
BH3 profiling and exon sequencing analysis, 13 (33%) harbored 
mutations or deletions of EZH2, EED, or SUZ12 (Fig. 1 D; Tables 
S1, S4, and S5). Nine of the PRC2 mutant cases harbored trun-
cating mutations, which included seven cases with frameshift 
or stop mutations predicted to induce premature termination of 
translation and two cases with heterozygous deletions involving 
EED. An additional four cases harbored missense or splice region 
variants of unknown significance. PRC2 truncating mutations 
were associated with resistance to mitochondrial apoptosis, an 
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Figure 1. PRC2 mutations are associated with resistance to mitochondrial apoptosis in human T-ALL. (A) T-ALL blasts were collected before the initia-
tion of chemotherapy from children treated on DFCI 05001 or COG AALL0434 clinical trials, and BH3 profiling analysis was performed to assess mitochondrial 
apoptotic priming, based on the degree of mitochondrial depolarization in response to 0.3 µM BIM peptide. Results were compared with the degree of residual 
leukemia in the bone marrow following the initial induction phase of combination chemotherapy. P = 0.008 by Welch t test. Number of samples per group: MRD 
≥ 10%, n = 4; MRD < 10%, n = 37. Each data point represents percent mitochondrial depolarization in an independent patient sample. (B and C) Comparison 
of event-free survival (P = 0.0376 by log-rank test; B) and overall survival (P = 0.091 by log-rank test; C) among T-ALL cases classified as apoptosis sensitive or 
resistant based on whether mitochondrial depolarization was above or below the mean. Number of samples per group: apoptosis sensitive, n = 24; apoptosis 
resistant, n = 23. (D) Targeted exome sequencing and array CGH revealed mutations or deletions of EZH2, EED, or SUZ12 in 13 of 40 T-ALL cases analyzed by both 
BH3 profiling and sequencing analysis. (E) Association of PRC2 genotype with percent mitochondrial depolarization by BH3 profiling in primary T-ALL patient 
samples. Truncating mutations were defined as stop or frameshift mutations predicted to result in premature termination of translation or deletions identified 
by array CGH analysis. Variants of unknown significance are missense substitutions or splice region variants of unknown functional consequence. Each data 
point represents percent mitochondrial depolarization in an independent patient sample. Color of each circle reflects the allelic nature of the mutation in each 
sample (blank circle, WT); cases with two distinct heterozygous mutations of the same gene were presumed to have biallelic mutations. P = 0.007 by Welch t 
test for truncating mutations versus WT cases. The significance of other comparisons was not assessed. Number of samples per group: truncating mutation, n 
= 9; variant of unknown significance, n = 4; WT, n = 27. (F) Association of PRC2 mutation type with resistance to induction chemotherapy. P = 0.040 by Welch t 
test for truncating mutations versus WT cases. The significance of other comparisons was not assessed. Number of samples per group: truncating mutation, n 
= 9; variant of unknown significance, n = 13; WT, n = 85. (G and H) Comparison of event-free survival (P = 0.09 by log-rank test; G) and overall survival (P = 0.87 
by log-rank test; H) among T-ALL cases by PRC2 mutation type. Note that the data shown in F–H include T-ALL cases analyzed by BH3 profiling and genomic 
analyses shown in A–E, as well as an additional cohort of T-ALL cases subjected to sequencing analysis only, on which BH3 profiling data were not available 
(see Table S1). Number of samples per group: WT, n = 85; truncating mutations, n = 9; variant of unknown significance, n = 13. (I) Validation of the association 
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effect that was similar in cases with monoallelic or biallelic PRC2 
mutations (Fig. 1 E).
We then asked whether PRC2 mutations predict treatment re-
sponse in T-ALL. For this, we included all T-ALL cases analyzed by 
sequencing analysis, which included 67 cases in addition to those 
analyzed by BH3 profiling (Table S1). In this larger cohort, 22 of 
107 T-ALL cases (20.5%) harbored PRC2 mutations. This revealed 
that truncating PRC2 mutations were associated with a poor re-
sponse to induction chemotherapy, with a trend toward inferior 
event-free survival that did not reach statistical significance 
(Fig. 1, F and G), but there was no difference in overall survival 
(Fig. 1 H). PRC2 mutations have been reported to be particularly 
common among T-ALL cases with the so-called early T cell pre-
cursor (ETP) immunophenotype (Zhang et al., 2012), which is 
linked to poor clinical outcome in some cohorts (Coustan-Smith 
et al., 2009; Gutierrez et al., 2010), but PRC2 mutations were 
more strongly linked to apoptosis resistance than ETP status 
(Table S2). To validate the association of PRC2 mutations with 
inferior clinical outcome in an independent cohort, we leveraged 
a separate cohort of T-ALL diagnostic clinical specimens previ-
ously subjected to genomic analysis (Zhang et al., 2012), which 
revealed that truncating PRC2 mutations were associated with 
inferior survival in this independent cohort (Fig. 1 I). The PRC2 
complex has been implicated as a tumor suppressor in T-ALL 
(Ntziachristos et al., 2012; Simon et al., 2012; Zhang et al., 2012; 
Danis et al., 2016), but whether PRC2 regulates mitochondrial 
apoptosis is unknown.
PRC2 depletion induces resistance to mitochondrial 
apoptosis in T-ALL
To test whether PRC2 regulates mitochondrial apoptosis in T-ALL, 
we began by depleting EZH2, a catalytic PRC2 subunit, from a 
panel of human T-ALL cell lines using RNA interference. BH3 pro-
filing was then performed to assess the ability of BIM peptide 
to induce cytochrome c release, indicating mitochondrial outer 
membrane permeabilization. EZH2 depletion induced mitochon-
drial apoptosis resistance in most of the cell lines tested (Fig. 2 A). 
To confirm that this phenotype was PRC2-dependent, we depleted 
EED or SUZ12, which encode core PRC2 components and found 
that this phenocopied the effect of EZH2 depletion on mitochon-
drial priming (Fig. 2, B and C). To test whether PRC2 also regulates 
chemotherapy-induced apoptosis, we treated CCRF-CEM T-ALL 
cells depleted of PRC2 core components with a panel of chemo-
therapeutics that form the backbone of contemporary T-ALL ther-
apy. PRC2 depletion induced resistance to apoptosis induction, 
as assessed by caspase 3/7 activity or by annexin V/propidium 
iodide staining, by a broad range of chemotherapeutics with 
distinct mechanisms of action (Fig. 2, D and E). Of note, EZH2 
depletion had no significant effect on cell cycle distribution of 
these cells (data not shown) and induced resistance to drugs such 
as dexamethasone and asparaginase that are cytotoxic to both 
proliferating and nonproliferating leukemic cells (Mauer, 1975).
To test whether regulation of mitochondrial apoptosis is 
dependent on the catalytic activity of PRC2, we tested whether 
shRNA depletion of endogenous EZH2 could be rescued by restor-
ing expression of WT EZH2 or of an EZH2 mutant with impaired 
methyltransferase catalytic activity (Kim et al., 2015). Apoptosis 
resistance upon EZH2 depletion was rescued by expression of a 
WT EZH2 transgene that escapes shRNA targeting, but not by the 
methyltransferase-defective mutant (Fig. 2, F–H). We then asked 
whether apoptosis induction following EZH2 depletion might be 
mediated by EZH1, based on recent findings that transcriptional 
activation after EZH2 depletion may be mediated by noncanoni-
cal EZH1-containing PRC2 complexes (Xu et al., 2015). However, 
combined knockdown of both EZH1 and EZH2 revealed that EZH1 
is not required for induction of apoptosis resistance following 
EZH2 inactivation (Fig. S2).
Depletion of the catalytic PRC2 subunit EZH2 induces 
chemotherapy resistance in T-ALL
To test whether EZH2 depletion improves leukemic cell fit-
ness upon chemotherapy treatment and to definitively rule out 
off-target shRNA effects, we then generated single-cell cloned 
isogenic EZH2-haploinsufficient or control T-ALL cells. Parental 
CCRF-CEM cells were first transduced with Cas9 and a guide RNA 
(gRNA) targeting exon 5 of EZH2, and single-cell cloning yielded 
an EZH2 mutant clone harboring mutations in three of the four 
alleles in this tetraploid cell line (Table S7), which we termed 
clone E. This EZH2-deficient clone exhibited low protein levels 
of EZH2 and of trimethylated histone H3 lysine 27 (the histone 
mark placed by EZH2) by Western blot analysis (Fig. 3 A), and 
resistance to mitochondrial apoptosis by BH3 profiling (Fig. 3 B), 
when compared with Cas9-transduced parental controls. Impor-
tantly, both of these effects were rescued by the transduction 
of WT EZH2, but not by a catalytically impaired EZH2 mutant 
(Fig. 3, A and B), indicating that they are caused by loss of EZH2 
enzymatic activity. We then treated control (Cas9 parental) or 
EZH2 mutant clone E cells with a 2-d pulse of vincristine, fol-
lowed by a subsequent release from chemotherapy. EZH2 mutant 
cells remained sensitive to vincristine-induced growth suppres-
sion, but had a significant survival advantage upon chemother-
apy treatment, as indicated by their improved ability to grow out 
after release from vincristine (Fig. 3 C).
We then asked whether the fitness advantage of EZH2 mu-
tant cells remains in co-culture experiments, an experimental 
design that ensures identical experimental conditions. For this, 
we first transduced EZH2 mutant clone E cells with EGFP, and 
Cas9-transduced parental controls with tdTomato, sorted cells 
with successful expression of the fluorescent marker, and mixed 
these in a 1:1 ratio. These cells were then subjected to 48-h pulses 
of treatment with various chemotherapeutics, followed by a 4-d 
release, and relative abundance of each clone was assessed by 
flow cytometry. This revealed that EZH2 mutant clone E cells 
had significantly improved fitness following treatment with 
of PRC2 mutations with outcome in an independent cohort of T-ALL cases treated on St. Jude or Associazione Italiana di Ematologia e Oncologia Pediatrica 
clinical trials and subjected to sequencing and copy number analyses, as described (Zhang et al., 2012). P = 0.002 by log-rank test. Number of samples per 
group: WT, n = 57; truncating mutations, n = 19; variant of unknown significance, n = 3. *, P ≤ 0.05; **, P ≤ 0.01; n.s., P > 0.05.
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Figure 2. PRC2 depletion induces resistance to chemotherapy-induced apoptosis in human T-ALL. (A) The indicated human T-ALL cell lines were trans-
duced with shRNA targeting EZH2 or Luciferase control, and knockdown efficacy was assessed using Western blot analysis (top). FACS-based BH3 profiling 
was then performed to assess the degree of cytochrome c release following treatment with 1 µM BIM peptide for 30 min (bottom). BH3 profiling results 
were normalized to shLuc control for each cell line. P < 0.0001 for CCRF-CEM, P < 0.0001 for DND41, P < 0.0001 for PF382, P < 0.001 for MOLT4, P = 0.99 for 
RPMI8402, and P = 0.003 for Jurkat, as assessed using two-way ANO VA with a Sidak adjustment for multiple comparisons between shLuc and shEZH2 only for 
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not only vincristine, but also with a broad range of chemother-
apeutic drugs with distinct mechanisms of action (Fig. 3 D). To 
rule out the possibility that this effect was unique to this EZH2 
mutant clone, we used an alternative experimental approach 
that avoided single-cell cloning. We first identified CRI SPR/Cas9 
gRNAs (gRNAs) targeting the catalytic SET domain of EZH2 or 
the AAVS1 safe-harbor locus (Sadelain et al., 2012; n = 4 gRNAs 
for each locus) and ensured that each of these gRNAs efficiently 
cut their target locus (data not shown). A pool of CCRF-CEM cells 
were then transduced with this pool of gRNAs and subsequently 
treated with a 48-h pulse of vincristine (or vehicle control), fol-
lowed by a release from drug treatment (Fig. 3 E). Analysis of 
gRNA representation 14 d after the start of vincristine treatment 
revealed a significant enrichment of all of the EZH2-targeting 
gRNAs following vincristine treatment (Fig. 3 F).
To test the in vivo relevance of these findings, we injected 
mice with equal amounts of EZH2 mutant clone E cells labeled 
with EGFP, and Cas9-transduced control cells labeled with tdTo-
mato. 7 d after injection, mice were treated with vehicle or vin-
cristine (n = 5 mice per group; Fig. 3 G). Mice were harvested 
on day 19 after injection, and the relative abundance of EZH2 
mutant versus parental clones was assessed by flow cytometry. 
This revealed that EZH2 mutant T-ALL cells had a significant in 
vivo fitness advantage following treatment with chemotherapy 
(Fig. 3, H and I). Collectively, these findings indicate that EZH2 
inactivation induces chemotherapy resistance in T-ALL.
Haploinsufficiency for the core PRC2 components Ezh2 or Eed 
is sufficient to induce mitochondrial apoptosis resistance in 
mouse thymocytes
We then asked whether PRC2 regulates mitochondrial apopto-
sis during normal T cell development. Mx1: Cre transgenic mice, 
which were either WT, heterozygous, or homozygous for floxed 
Ezh2 or Eed alleles ((Shen et al., 2008; Neff et al., 2012), were 
treated with polyinosine-polycytosine acid (pIpC) to induce Cre 
activity in hematopoietic cells. Subsequently, thymocytes were 
harvested and stained for markers of T cell developmental stage, 
and mitochondrial apoptotic priming was assessed using BH3 
profiling (Fig. 4, A and B). Haploinsufficiency for either Ezh2 
or Eed was sufficient to induce apoptosis resistance in late dou-
ble-negative thymocytes, but not at more mature stages of T cell 
development (Fig. 4, C and D). Ezh2 or Eed haploinsufficiency did 
not significantly alter thymocyte numbers at the stages of thymo-
cyte development assessed (data not shown), but we were unable 
to perform BH3 profiling in Ezh2 or Eed homozygous knockout 
thymocytes because the thymus of these mice was markedly hy-
pocellular and populated by thymocytes that escaped biallelic 
gene deletion (data not shown), suggesting that the previously 
described requirement for Ezh2 in normal T cell development is 
PRC2-dependent (Su et al., 2005; Simon et al., 2012).
TRAP1 overexpression is necessary for induction of 
mitochondrial apoptosis resistance downstream of 
PRC2 inactivation
We then turned our attention to the mechanism linking PRC2 
to the mitochondrial apoptotic machinery. PRC2 is best known 
as a chromatin-modifying complex whose activity is associated 
with transcriptional repression (Margueron and Reinberg, 2011). 
Thus, we began by investigating genes whose transcription is 
up-regulated upon depletion of PRC2, using RNA-seq of T-ALL 
cells depleted of PRC2 core components (Table S8). A recent 
study has shown that EZH2 loss induces chemotherapy resis-
tance in acute myeloid leukemia in association with HOXB7 and 
HOXA9 up-regulation and undefined downstream consequences 
(Göllner et al., 2017), but PRC2 knockdown did not up-regulate 
expression of any HOXA or HOXB cluster gene in these cells (data 
not shown). PRC2 depletion had no consistent effects on tran-
scription of any of the known pro- or antiapoptotic BCL2 family 
genes (Fig. S3), suggesting that PRC2 regulates mitochondrial 
priming via alternative apoptotic regulators.
PRC2 depletion induced apoptosis resistance as assessed by 
BH3 profiling, an assay performed after cytoplasmic membrane 
permeabilization and release of at least some soluble cytoplas-
mic proteins. Thus, we reasoned that PRC2 was likely to regulate 
mitochondrial apoptosis via factors intrinsic to, or stably associ-
ated with, the mitochondria. Analysis of the genes most signifi-
each cell line. (B and C) CCRF-CEM cells were transduced with shRNAs targeting EED, SUZ12, or Luciferase control, and knockdown efficacy was assessed using 
quantitative reverse transcription PCR (B, top) or Western blot analysis (C, top). BH3 profiling was then performed as in (A, bottom). Significance was assessed 
by one-way ANO VA with Tukey adjustment for multiple comparisons. P values for shLuc versus shEED no. 2 = 0.0012 and shLuc versus shEED no. 5 = 0.0004 
in B; P values for shLuc versus shSUZ12 no. 2 < 0.0001; shLuc versus shSUZ12 no. 3 = 0.0009 in C. (D) CCRF-CEM cells were transduced with shRNAs targeting 
EZH2, EED, SUZ12, or Luciferase control, treated with vehicle (PBS) or each of the indicated chemotherapeutic agents, and apoptosis induction was assessed 
by caspase 3/7 activity assay. Results were normalized to vehicle-treated shLuc cells. Significance was assessed by two-way ANO VA with a Sidak adjustment 
for multiple comparisons between control or PRC2-targeting shRNA only for each drug. For shLuc versus shEZH2, P = 1.00 for PBS and < 0.0001 for all other 
drugs; for shLuc versus shEED, P = 0.99 for PBS and < 0.0001 for all other drugs; for shLuc versus shSUZ12, P = 0.98 for PBS, P = 0.54 for dexamethasone, 
and P < 0.0001 for all other drugs. (E) CCRF-CEM cells were transduced with the indicated shRNAs, treated with the indicated chemotherapeutic drugs, and 
cell death was assessed using annexin V and propidium iodide staining. Significance was assessed by two-way ANO VA with a Sidak adjustment for multiple 
comparison between shRNAs only for each drug. For all comparisons, P < 0.0001 except P = 0.0007 for shLuc versus shEED in asparaginase-treated condi-
tions. (F) Schema of experimental design to rescue shEZH2-induced resistance to chemotherapy-induced apoptosis using doxycycline-inducible transgenes 
encoding WT EZH2, or a catalytically defective triple mutant of EZH2. The EZH2 shRNA used targets the 3′UTR of the endogenous gene, which is not present 
in the EZH2 transgenes used for rescue. (G) CCRF-CEM cells manipulated as shown in F were subjected to Western blot analysis for the indicated proteins. 
(H) CCRF-CEM cells experimentally manipulated as shown in F were treated with nelarabine for 48 h, and induction of apoptosis was assessed by caspase 3/7 
activity assay. Significance was assessed by one-way ANO VA with Tukey adjustment for multiple comparisons. P = 0.01 for shEZH2 –dox versus shEZH2 +dox 
in cells transduced with doxycycline-inducible WT EZH2; P = 1.00 for shEZH2 −dox versus shEZH2 +dox in cells transduced with doxycycline-inducible mutant 
EZH2. All bar charts represent the mean ± SEM of at least n = 3 biological replicates from one representative experiment, and each experiment was repeated 
independently at least twice. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; n.s., P > 0.05.
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Figure 3. EZH2 depletion induces chemotherapy resistance in T-ALL. (A) CCRF-CEM cells were transduced with Cas9 and EZH2 targeting gRNA, sin-
gle-cell cloned, and next-generation sequencing was used to identify a clone with EZH2 haploinsufficiency (EZH2 mutant clone E). Western blot analysis 
was performed to assess expression of the indicated proteins in basal conditions or following transduction with doxycycline-induced constructs encoding 
WT EZH2 or a catalytically defective triple mutant. One representative experiment is shown, which was repeated independently. (B) BH3 profiling was 
performed on the cells shown in A. Results shown are the mean ± SEM of n = 3 biological replicates. Significance was assessed by one-way ANO VA with 
Tukey adjustment for multiple comparisons. P = 0.017 for parental Cas9 versus EZH2 mutant clone; P = 0.004 for clone E transduced with EZH2 WT versus 
EZH2 catalytic mutant. Bar charts represent the mean of three biological replicates, and the experiment was repeated independently. (C) EZH2 mutant 
clone E cells or their parental Cas9 controls were treated with the indicated doses of vincristine for 48 h and then released from chemotherapy. Viable cell 
counts were obtained by trypan blue exclusion at the indicated time points. Significance assessed by Welch t test (P = 0.07 for untreated EZH2 mutant 
versus untreated parental Cas9; P = 0.006 for vincristine-treated EZH2 mutant versus vincristine-treated parental Cas9). Results shown are the mean ± 
SEM of n = 3 biological replicates. Representative data of at least two independent experiments shown. (D) EGFP-transduced EZH2 mutant clone E cells 
were mixed at 1:1 ratio with tdTomato-transduced parental Cas9 controls. The resultant pool of cells was treated with vehicle control or the indicated 
chemotherapeutics for 48 h and subsequently released from chemotherapy. Relative abundance of each clone was assessed by flow cytometry analysis 4 d 
after chemotherapy release. Results are normalized to the abundance of each clone in nonchemotherapy-treated controls. Significance assessed by Welch 
t test, with P < 0.0001 for vincristine, P = 0.0281 for etoposide, P = 0.0003 for cytarabine, P = 0.0008 for doxorubicin, and P = 0.0004 for methotrexate. 
Results shown are the mean ± SEM of n = 3 biological replicates, and the experiment was repeated independently. (E) Experimental design to assess 
relative fitness of CCRF-CEM cells transduced with gRNAs targeting the catalytic domain of EZH2, or the AAVS1 safe-harbor genomic locus, in control or 
chemotherapy-treated conditions. (F) CCRF-CEM cells manipulated as shown in E were treated with 30 nM vincristine or vehicle for 48 h, released from 
vincristine for 12 d, and gRNA representation was assessed by next-generation sequencing. Relative abundance of each gRNA was normalized to its abun-
dance in vehicle-treated controls. Significance assessed by Welch t test; P = 0.0001. (G) Experimental design to assess in vivo chemosensitivity of EZH2 
mutant clone E cells or their parental Cas9 controls in NRG-immunodeficient mice. (H) FACS analysis of splenic cells harvested from mice after treatment 
as indicated in G. Each bar is the mean of five independent mice. Significance was assessed by Welch t test; P = 0.0026. (I) Representative FACS plots from 
mice analyzed in H. Control mice without fluorescent leukemia are shown as the negative control for setting FACS gates. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 
0.001; ****, P ≤ 0.0001; n.s., P > 0.05.
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cantly up-regulated following PRC2 depletion revealed a single 
transcript known to encode a mitochondrial protein, TRAP1 
(Fig. 5 A). TRAP1 is a nuclearly encoded, mitochondrially local-
ized chaperone of the HSP90 family (Felts et al., 2000; Kang et 
al., 2007). Using Western blot analysis, we confirmed that PRC2 
depletion up-regulates TRAP1 protein expression (Fig. 5 B). Anal-
ysis of Trap1 mRNA expression in mouse Ezh2-haploinsufficient 
versus control thymocytes revealed increased Trap1 mRNA ex-
pression in Ezh2-haploinsufficient cells (Fig. 5 C), indicating that 
TRAP1 regulation by EZH2 is evolutionarily conserved.
Figure 4. Haploinsufficiency for the core PRC2 components Ezh2 or Eed is sufficient to induce mitochondrial apoptosis resistance in mouse thy-
mocytes. (A) Schema of experimental design. (B) FACS gating and sorting strategy to isolate thymocytes at the indicated developmental stages. Negative 
sorting was also performed to exclude cells expressing B cell, NK cell, red blood cell, or granulocytic markers. (C and D) Mx1: Cre transgenic, Ezh2 fl/WT (n = 
5) or WT/WT (n = 6) siblings were treated with pIpC, and thymocytes were harvested as indicated in A and stained with a panel of antibodies to determine T 
cell developmental stage (B). PCR was performed on genomic DNA to verify appropriate deletion of Ezh2 (C, top). Stained thymocytes were subjected to BH3 
profiling analysis using 1 µM BIM peptide for 25 min, and cytochrome c release was assessed by stage of T cell development using FACS analysis (C, bottom). 
Results are shown for all stages of T cell development that consistently yielded >250 FACS events for analysis. Significance was assessed by two-way ANO VA 
with Sidak adjustment for multiple comparisons between WT/WT versus fl/WT only for each stage of T cell development. P = 0.0066 for DN3, 0.049 for DN4, 
0.44 for immature single positive (ISP), 0.96 for double positive (DP), 1.0 for CD8 SP, and 0.94 for CD4 SP. (D) Mx1: Cre transgenic, Eed fl/WT (n = 12) or WT/
WT (n = 9) siblings were treated with pIpC, and thymocytes were harvested as indicated in A. PCR was performed to verify Eed deletion (D, top), and staining 
for T cell developmental markers and BH3 profiling analysis were performed as in D (bottom). Results are shown for all stages of T cell development that con-
sistently yielded >250 FACS events for analysis. Significance was assessed by two-way ANO VA with Sidak adjustment for multiple comparisons between WT/
WT versus fl/WT only for each stage of T cell development. P = 0.37 for DN3, 0.0017 for DN4, 0.76 for ISP, 1.0 for DP, 0.96 for CD8 SP, and 1.0 for CD4 single 
positive (SP). *, P ≤ 0.05; **, P ≤ 0.01; n.s., P > 0.05.
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Figure 5. TRAP1 overexpression is necessary for induction of mitochondrial apoptosis resistance downstream of PRC2 inactivation. (A) CCRF-CEM 
human T-ALL cells were transduced with the indicated shRNAs, and RNA-seq was performed. Heat map depicts the genes most highly up-regulated following 
PRC2 depletion, based on DES EQ2 analysis for differentially expressed genes. Blue arrow denotes mitochondrial localized proteins; orange arrows denote genes 
whose loci are marked by H3K27me3 on ChIP-seq analysis (as investigated further in Fig. 6). (B) Western blot analysis for the indicated proteins in CCRF-CEM 
cells transduced with the indicated shRNA. The experiment was repeated twice, and a representative blot is shown. (C) Mx1: Cre transgenic, Ezh2 fl/WT or WT/
WT siblings were treated with pIpC 4 wk after birth, and thymocytes were harvested 12 wk after birth. PCR was performed to verify excision of Ezh2 (left). Mouse 
thymocytes of the indicated developmental stages were FACS sorted and subjected to qRT-PCR analysis for Gapdh and Trap1 (right). Data points represent the 
mean expression of individual mice, with two mice analyzed per genotype. Significance was assessed by two-way ANO VA including main effect terms (using 
an F test) for Ezh2 genotype and T cell developmental stage (P = 0.0001). No interaction term was included in the model, so pairwise comparisons were not 
assessed. (D) The indicated human T-ALL cells were transduced with doxycycline-inducible, neomycin-resistant constructs encoding GFP or TRAP1. Western 
blot analysis was performed to assess expression of the indicated proteins (top) 72 h after the start of doxycycline treatment. At that time point, cells were 
treated with the indicated chemotherapeutics for 48 h, and apoptosis induction was assessed using a caspase 3/7 activity assay. Significance was assessed by 
two-way ANO VA with a Sidak adjustment for multiple comparisons between GFP and TRAP1 only for each treatment. For CCRF-CEM cells, P = 0.25 for DMSO 
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We then asked whether TRAP1 overexpression is sufficient 
to induce resistance to chemotherapy-induced apoptosis in cells 
with physiological PRC2 activity. Transduction of TRAP1 into 
human T-ALL cell lines induced partial resistance to chemother-
apy-induced apoptosis (Fig. 5 D). To test whether TRAP1 over-
expression is required for mitochondrial apoptosis resistance 
following PRC2 inactivation, we used RNA interference to deplete 
either EZH2 or control, in combination with depletion of TRAP1 
or shLuciferase control. Depletion of TRAP1 completely blocked 
the emergence of apoptosis resistance following EZH2 knock-
down (Fig. 5 E and Fig. S4). We also took advantage of gamitrinib, 
an ATP-competitive small molecule inhibitor of HSP90-family 
chaperones that inhibits mitochondrial TRAP1 and HSP90 func-
tion by virtue of its specific mitochondrial localization (Kang et 
al., 2009). While gamitrinib had some toxicity to control T-ALL 
cells, EZH2-depleted cells demonstrated increased sensitivity 
to this drug (Fig. 5 F), indicating that PRC2 deficiency imparts 
an increased dependence on mitochondrial chaperone function. 
Furthermore, gamitrinib had synergistic antileukemic activity 
in combination with dexamethasone or doxorubicin at highly 
effective dose combinations (Fig. 5 G).
PRC2 induces TRAP1 expression and mitochondrial apoptosis 
resistance via CRIP2
To define how PRC2 regulates TRAP1 expression, we performed 
chromatin immunoprecipitation-sequencing (ChIP-seq) analysis 
for the histone mark placed by PRC2, trimethylated histone H3 
lysine 27 (H3K27me3), in CCRF-CEM cells (Table S9). We noted 
that there were no significant H3K27me3 peaks detected in CCRF-
CEM cells following EZH2 knockdown (data not shown), indicat-
ing that EZH2 is the primary H3K27me3 methyltransferase in 
these cells. Analysis of ChIP-seq in PRC2 proficient CCRF-CEM 
cells revealed no detectable H3K27me3 at the TRAP1 locus (data 
not shown), indicating that regulation of TRAP1 by PRC2 is indi-
rect. To identify the relevant direct target(s) of PRC2 that regulate 
TRAP1 expression and apoptosis resistance, we first combined 
ChIP-seq and RNA-seq analysis to define the direct canonical 
transcriptional targets of PRC2, defined as genes whose loci were 
marked by H3K27me3 at baseline and whose RNA expression in-
creased following PRC2 depletion (Fig. 5 A). We then transduced 
each of these genes individually into T-ALL cells, to define those 
that regulate TRAP1 expression and mitochondrial apoptosis re-
sistance using quantitative reverse transcription PCR (qRT-PCR) 
and BH3 profiling analysis, respectively. We found that CRIP2 was 
the direct PRC2 target whose up-regulation most strongly induced 
apoptosis resistance and TRAP1 expression (Fig. 6, A and B).
CRIP2 encodes a LIM (named after the LIN-11, ISL-1, and 
MEC-3 proteins in Caenorhabditis elegans)-only domain protein 
that has been implicated as a transcriptional regulator of NF-κB 
signaling in nasopharyngeal carcinoma (Cheung et al., 2011). We 
confirmed that EZH2 depletion induced expression of CRIP2 in 
T-ALL cells (Fig. 6 C) and that Ezh2 haploinsufficiency induced 
Crip2 expression in nontransformed mouse T cell progenitors 
(Fig. 6 D). To test whether Crip2 up-regulation is necessary for 
induction of apoptosis resistance following Ezh2 inactivation, 
we combined transduction of one shRNA, targeting either EZH2 
or empty vector control, with a second shRNA, targeting either 
CRIP2 or shLuciferase control. CRIP2 knockdown completely 
prevented the ability of EZH2 depletion to induce resistance to 
several chemotherapeutics with distinct mechanisms of action 
(Fig. 6 E and Fig. S5). BH3 profiling and qRT-PCR analysis of T-ALL 
cells transduced with EGFP or CRIP2 revealed that CRIP2 over-
expression is sufficient to induce TRAP1 mRNA up-regulation 
and resistance to mitochondrial apoptosis (Fig. 6 F). In a panel of 
primary T-ALL cells that have been expanded in immunocompro-
mised mice, treatment with the EZH2 inhibitor GSK126 induced 
transcriptional regulation of both CRIP2 and TRAP1 (Fig. 6 G). 
Moreover, RNA-seq analysis of primary T-ALL patient samples 
revealed that expression of CRIP2 and TRAP1 were strongly pos-
itively correlated (Fig. 6 H). We then asked whether TRAP1 over-
expression predicts chemotherapy failure in childhood T-ALL. We 
classified patients into TRAP1 high or low groups based on mean 
TRAP1 expression in pretreatment T-ALL lymphoblast specimens 
and compared survival among these groups. TRAP1 up-regula-
tion predicted inferior event-free and overall survival in children 
with T-ALL treated on recent clinical trials (Fig. 6 I). Collectively, 
these findings support a model in which loss of PRC2 induces 
transcriptional up-regulation of its direct target CRIP2, which 
subsequently activates expression of the mitochondrial chaper-
one TRAP1, leading to resistance to chemotherapy-induced mito-
chondrial apoptosis (Fig. 6 J).
Discussion
The studies described here demonstrate that PRC2 genotype pro-
vides one molecular explanation for phenotypic variability in mi-
and P < 0.0001 for all drugs. For PF382, P = 0.0048 for DMSO and P < 0.0001 for all other drugs. For RPMI 8402, P = 0.0002 for DMSO and P < 0.0001 for all 
other drugs. Results shown are the mean ± SEM of n = 3 biological replicates of a representative experiment, all of which were repeated at least twice. (E) 
CCRF-CEM cells were transduced with a neomycin-resistant “shRNA 1” targeting EZH2 or empty vector control and a puromycin-resistant “shRNA 2” targeting 
either TRAP1 or Luciferase control. Following antibiotic selection, cells were treated with the indicated chemotherapeutics for 48 h, and apoptosis induction was 
assessed using a caspase 3/7 activity assay. Differences were assessed by two-way ANO VA analysis, with Tukey adjustment for multiple comparisons. In all three 
drug conditions, P < 0.0001 for the comparison of shVector-shLuc versus shEZH2-shLuc–transduced cells, and P < 0.0001 for shEZH2-shLuc versus shEZH2- 
shTRAP1–transduced cells. Results shown are the mean ± SEM of n = 3 biological replicates from a representative experiment, all of which were repeated at 
least twice. (F) CCRF-CEM cells were transduced with the indicated shRNAs, treated with gamitrinib at the indicated doses, and viability was assessed using 
Cell TiterGlo. Differences were assessed by two-way ANO VA analysis with Sidak adjustment for multiple comparisons between shLuc and shGFP only for each 
gamitrinib dose. P = 0.97 for DMSO, P = 0.023 at 1 µM, and P < 0.0001 at 5 µM. Results shown are the mean ± SEM of n = 3 biological replicates from a rep-
resentative experiment, which was repeated independently. (G) CCRF-CEM cells were transduced with shEZH2 no. 1, treated with gamitrinib in combination 
with either dexamethasone or doxorubicin at a range of doses, and viability was assessed using Cell TiterGlo. Synergy was assessed using combination index 
analysis. Data are shown for dose combinations with fractional inhibition of 0.2–0.95. Note synergistic interactions (combination index < 0.7) at dose combina-
tions approaching maximal efficacy, as assessed by fractional inhibition of cell viability. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; n.s., P > 0.05.
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Figure 6. PRC2 regulates TRAP1 overexpression via CRIP2. (A) Direct canonical transcriptional targets of PRC2, defined as genes whose loci are marked 
by H3K27me3 at baseline and whose transcription is activated following PRC2 depletion, were transduced individually into human CCRF-CEM T-ALL cells. BH3 
profiling (1 µM BIM peptide for 25 min) and qRT-PCR analysis were used to assess induction of apoptosis resistance and TRAP1 mRNA expression, respectively, 
and each is shown normalized to levels in EGFP-transduced control cells. Note that overexpression of the direct PRC2 targets PHL DB1, MXRA7, and TSP AN9 
was toxic to CCRF-CEM cells; thus, these targets were not investigated further. Results shown are the mean ± SEM of n = 3 biological replicates. (B) ChIP-seq 
for H3K27me3 at the CRIP2 locus in PRC2-proficient CCRF-CEM cells. (C) CCRF-CEM cells were transduced with the indicated shRNAs and subjected to qRT-PCR 
Ariës et al. 
PRC2 loss induces chemoresistance in T-ALL
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180570
12
tochondrial apoptotic priming between chemotherapy-sensitive 
versus resistant T-ALL cell populations. Thus, PRC2 function is 
a key molecular determinant of treatment response in T-ALL. 
PRC2 haploinsufficiency was sufficient to induce apoptosis re-
sistance in nontransformed T cell progenitors, suggesting that 
chemotherapy resistance can evolve before oncogenic transfor-
mation. These findings thus provide a model in which the muta-
tional path to T cell transformation, which evolves in the absence 
of chemotherapy-induced selective pressure, can nevertheless 
result in the formation of a highly chemoresistant leukemic clone 
if the genetic lesions acquired result in high-level resistance to 
mitochondrial apoptosis.
We found that PRC2 mutations predict early treatment fail-
ure in independent cohorts of childhood T-ALL, in line with the 
previously reported association of EZH2 inactivation with treat-
ment failure in T-ALL (Zhang et al., 2012) and in acute myeloid 
leukemia (Göllner et al., 2017). Of note, this association was not 
observed in a recent whole genome–sequencing study of T-ALL 
(Liu et al., 2017), but cases of primary chemotherapy resistance 
appear to have been excluded from this study because their 
post-chemotherapy specimens harbored leukemia, and there was 
no alternative source of germline DNA available for the whole 
genome–sequencing approach applied. It will be of considerable 
interest to prospectively validate the ability of PRC2 mutations to 
predict primary chemotherapy resistance in future clinical trials.
Deletion of PRC2 genes induced apoptosis resistance at late 
double-negative stages of T cell development, but not in more 
mature T cell progenitors. PRC2 function can be highly con-
text dependent for reasons that are not well understood, even 
in seemingly related cell types. For example, while EZH2 is a 
tumor suppressor in immature lymphocytes of the T cell lineage 
(Simon et al., 2012; Danis et al., 2016), it functions as a driver 
oncogene in B-lineage lymphocytes (Souroullas et al., 2016). In T 
cell progenitors, we note that the switch from PRC2-dependent to 
PRC2-independent regulation of mitochondrial apoptosis occurs 
in association with profound changes in regulation of apoptosis 
by TCR signaling. Thus, one speculative possibility is that loss 
of PRC2-dependent transcriptional repression may potenti-
ate preTCR-driven survival signaling in double-negative T cell 
progenitors, where this triggers antiapoptotic signals. As these 
cells mature, PRC2 loss may cease to be antiapoptotic as part of 
the switch to negative selection, where TCR signaling becomes 
pro-apoptotic (Klein et al., 2014).
Our data do not rule out a role for differential induction of 
BCL2 family proteins and mitochondrial apoptotic priming by 
chemotherapeutics as an additional determinant of treatment 
response. However, our findings implicate TRAP1 up-regulation 
as one important mechanism linking PRC2 loss to induction of 
mitochondrial apoptosis resistance in T-ALL. Indeed, TRAP1 was 
required for the induction of resistance to chemotherapy-in-
duced apoptosis upon PRC2 depletion, and pharmacologic TRAP1 
inhibition synergized with dexamethasone and doxorubicin, 
antileukemic drugs with distinct mechanisms of action. TRAP1 
is an HSP90 family chaperone that localizes to the mitochon-
drial inner membrane and inter-membrane space (Pridgeon et 
al., 2007). TRAP1 inhibits a nonapoptotic, caspase-independent 
form of cell death termed mitochondrial permeability transi-
tion-driven necrosis (Kang et al., 2007) and has also been shown 
to inhibit some features of mitochondrial apoptosis (Pridgeon 
et al., 2007; Costantino et al., 2009). While mitochondrial per-
meability transition-driven necrosis and BCL2-regulated mito-
chondrial apoptosis are distinct cell death pathways (Baines et 
al., 2005; Nakagawa et al., 2005; Galluzzi et al., 2015), these do 
share some cellular machinery (Karch et al., 2013), and it will be 
of interest to define precisely how TRAP1 regulates mitochon-
drial apoptosis.
The broad range of cytotoxic chemotherapeutics used for 
T-ALL therapy are used in combination because their distinct 
mechanisms of action impair emergence of resistance. How-
ever, our findings suggest that their antileukemic activity 
analysis for expression of the indicated genes. P values calculated by Welch t test (EZH2 mRNA, P = 0.0004; CRIP2 mRNA, P < 0.0001). Results shown are the 
mean ± SEM of n = 3 biological replicates from one representative experiment, which was repeated twice. (D) Mx1: Cre transgenic, Ezh2 WT/WT or fl/WT mice 
were treated with pIpC 4 wk after birth, and thymocytes were harvested 12 wk after birth. Thymocytes of the indicated developmental stages were FACS sorted 
and subjected to qRT-PCR analysis for Gapdh and Crip2 RNA expression. Results are shown from individual mice from n = 2 mice per group. Significance was 
assessed by two-way ANO VA including main effect terms (using an F test) for Ezh2 genotype and T cell developmental stage (P = 0.008). No interaction term 
was included in the model, so pairwise comparisons were not assessed. (E) CCRF-CEM cells were transduced with a neomycin-resistant “shRNA 1” targeting 
EZH2 or empty vector control and a puromycin-resistant “shRNA 2” targeting either CRIP2 or Luciferase control. Cells were then treated with the indicated 
chemotherapeutic drugs, and effects on apoptosis were assessed by caspase 3/7 activity. Differences were assessed by two-way ANO VA analysis, with Tukey 
adjustment for multiple comparisons. In vincristine- and cytarabine-treated cells, P < 0.0001 for shVector-shLuc versus shEZH2-shLuc and shEZH2-shLuc 
versus shEZH2-shCRIP2–transduced cells. In asparaginase-treated cells, P < 0.0036 for shVector-shLuc versus shEZH2-shLuc, and P < 0.0001 shEZH2-shLuc 
versus shEZH2-shCRIP2–transduced cells. Results shown are the mean ± SEM of n = 3 biological replicates from one representative experiment, which was 
repeated independently. (F) CCRF-CEM cells were transduced with CRIP2 or EGFP. qRT-PCR analysis was performed to assess expression of CRIP2 mRNA (top, 
P < 0.0001 by Welch t test) or TRAP1 mRNA (bottom right, P = 0.027 by Welch t test). Effects on mitochondrial apoptosis were assessed by BH3 profiling using 
1 µM BIM peptide for 25 min (bottom, P < 0.0001 by Welch t test). Results shown are the mean ± SEM of n = 3 biological replicates from one representative 
experiment, which was repeated independently. (G) T-ALL cells from primary patients were expanded in immunodeficient mice, harvested, treated in short-term 
culture with vehicle or 1 µM GSK126 for 6 d, and qRT-PCR analysis was performed for the indicated genes. P values calculated by Welch t test. For CRIP2, P = 
0.0001 for D115, P = 0.031 for D9, P = 0.0015 for FE849, P < 0.0001 for D12, and P = 0.0007 for D15. For TRAP1, P = 0.033 for D115, P = 0.16 for D9, P = 0.006 for 
FE849, P = 0.08 for D12, and P = 0.0001 for D15. Results shown are the mean ± SEM of n = 3 biological replicates from one representative experiment, which 
was repeated independently. (H) Correlation of CRIP2 and TRAP1 mRNA expression in RNA-seq data from primary T-ALL patient samples. Pearson correlation 
coefficient (r = 0.576) reported P value (P = 0.003) indicating a significant positive correlation between CRIP2 and TRAP1 RNA expression. (I) Comparison of 
event-free survival and overall survival among T-ALL cases on DFCI 05001 or COG AALL0434 clinical trials classified as TRAP1 high or low expressing based on 
whether RNA-seq TRAP1 expression was above or below the median. A one-sided log-rank test was performed due to the hypothesized direction of event-free 
survival (P = 0.028) and overall survival (P = 0.043) differences. Number of samples per group: TRAP1 low, n = 14; TRAP1 high, n = 10. (J) Proposed model to 
explain regulation of chemotherapy-induced apoptosis by PRC2. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; n.s., P > 0.05.
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nevertheless converges on a common downstream pathway, 
mitochondrial apoptosis, whose impairment is sufficient to si-
multaneously induce resistance to all chemotherapeutics that 
we tested. Our data implicate up-regulation of the LIM domain 
transcription factor CRIP2, and downstream activation of TRAP1 
chaperone functions as a key mediator of apoptosis resistance 
and clinical response to cytotoxic chemotherapy. These findings 
suggest that the clinical development of TRAP1 inhibitors may 
provide a therapeutic strategy to specifically reverse apoptosis 
resistance and improve clinical outcomes for patients with high-
risk subsets of T-ALL.
Materials and methods
Patient samples
113 diagnostic T-ALL samples were obtained from the bone mar-
row or peripheral blood of children before the initiation of che-
motherapy from children with newly diagnosed T-ALL enrolled 
on Dana-Farber Cancer Institute (DFCI) Study 05-001 (Place et 
al., 2015) or Children’s Oncology Group (COG) Study AALL0434. 
Of these, 47 had a suitable viably frozen specimen for BH3 pro-
filing, and the remainder were included in the sequencing anal-
yses only (Table S1). Samples were purified using Ficoll-Paque 
reagent before viable freezing or genomic DNA extraction. Viably 
frozen samples were stored in liquid nitrogen. All samples were 
collected with informed consent and Institutional Review Board 
(IRB) approval of the respective institutions, in accordance with 
the Declaration of Helsinki. End-induction minimal residual dis-
ease analysis was assessed by flow cytometry (COG AALL0434) 
or PCR analysis for T cell receptor gene rearrangements (DFCI 
05001) per the clinical standard on each protocol. The percent 
bone marrow blast cutoff used to define induction failure was 
different between these two clinical trials (≥5% on DFCI 05-001 
or ≥ 25% in COG AALL0434), therefore protocol-defined induc-
tion failure or ≥5% bone marrow blasts were considered equiva-
lent for the purposes of assessing the effect of PRC2 genotype on 
response to induction chemotherapy.
BH3 profiling of primary T-ALL patient samples
The sequence of the peptide mimetics of the BIM BH3 domain 
and inert PUMA2A negative control, as well as methods of syn-
thesis, were as previously described (Ni Chonghaile et al., 2011). 
BH3 profiling of 47 primary patient samples was performed 
using the plate-based fluorimetry method to assess effects of 
BIM BH3 peptide or PUMA2A negative control on mitochondrial 
membrane potential, as previously described (Chonghaile et al., 
2014). In brief, BH3 peptides at 70 μM/liter were plated in trip-
licate on a black 384-well plate. Cells were gently permeabilized 
with 0.005% digitonin and loaded with the fluorescent mito-
chondrial dye JC-1. The cells were plated on top of the peptides at 
2.5 × 10E4 cells per well. The loss of mitochondrial potential was 
measured on the Tecan Saffire2 at an excitation of 545 nm and 
an emission of 590 nm over 3 h. The percentage of mitochondrial 
depolarization for the peptides was calculated by normalization 
to the solvent-only control DMSO (0%) and the positive control 
carbonyl cyanide-4-(trifluoromethoxy)phenyl hydrazone (FCCP; 
100%) at 60 min.
Targeted exome sequencing of T-ALL patient samples
T-ALL diagnostic specimens were purified using Ficoll-Paque 
reagent and viably frozen. Genomic DNA (gDNA) was extracted 
using the AllPrep DNA/RNA mini kit (OPv1 cohort; Qiagen) or the 
DNeasy kit (OPv3mod cohort; Qiagen) according to the manufac-
turer’s instructions. Targeted exon sequencing was performed at 
the Center for Cancer Genome Discovery at the DFCI using an 
Illumina sequencing platform for all protein-coding exons of 
the genes shown in Table S3. In brief, 200 ng of double-stranded 
gDNA was fragmented to an average of 150 bp or 250 bp using 
Covaris ultrasonication (LE220 Focused-ultrasonicator; Cova-
ris). Fragmented DNA was purified using Agencourt AMPure XP 
beads (Beckman Coulter). Size-selected DNA was then ligated 
to sequencing adaptors using sample-specific barcodes, and li-
braries were constructed (SPRIworks HT; Beckman Coulter) 
and quantified using qPCR (Kapa Biosystems) or MiSeq (Illu-
mina, Inc.). For targeted exon enrichment, libraries were pooled 
in equal mass to a total of 500 ng, and regions of interest were 
captured using custom-designed baits (SureSelect Target Enrich-
ment system; Agilent Technologies). All captures were sequenced 
on the HiSeq 2500 platform (Illumina, Inc.) in Rapid Run Mode.
Pooled sample reads were deconvoluted and sorted using 
Picard tools. Reads were aligned to the reference sequence b37 
edition from the Human Genome Reference Consortium using 
Burrows-Wheeler Aligner using parameters “-q, 5; -l, 32; -k, 2; 
-o, 1.” Duplicate reads were removed using the Picard tools (Li 
and Durbin, 2009). The alignments were further refined using 
the Genome Analysis Toolkit for localized realignment around 
indel sites. Recalibration of the quality scores was also performed 
using Genome Analysis Toolkit tools (McKenna et al., 2010; 
DePristo et al., 2011).
Mutation analysis for single-nucleotide variants was per-
formed using MuTect v1.1.4 (Cibulskis et al., 2013) and annotated 
by Oncotator or Variant Effect Predictor (McLaren et al., 2010). 
MuTect was run in single or paired mode using internal control 
Centre d’Etude du Polymorphisme Humain as the “matched” 
normal in paired mode. We used the SomaticIndelDetector tool 
that is part of the Genome Analysis Toolkit for indel calling, as 
described previously (Abedalthagafi et al., 2014). Mutation calls 
were made for those variants predicted to result in a nonsynon-
ymous amino acid alteration, frameshift mutation, stop codon, 
or to alter a splice site and for variants with at least 10 reads of 
the mutant allele.
Germline variant filters were applied. Variants were filtered 
against the 6,500-exome release of the Exome Sequencing Project 
database and the Genome Aggregation Database (gnomAD v.2.0). 
Variants represented in either database at >0.1% frequency were 
excluded from further analysis. Catalogue of Somatic Mutations 
in Cancer (COS MIC v.80) annotations were added to the vari-
ant calls, if available. Sequencing was performed in two cohorts 
(OPv1 and OPv3mod) for the genes indicated in Table S3. In the 
OPv1 cohort, EED (NM_003797.3) was sequenced by Sanger se-
quencing at Genewiz, because this gene was not included in the 
OPv1 sequencing platform used. These data are from primary 
patient samples collected before the 2015 update of the National 
Institutes of Health (NIH) Genomic Data Sharing policy, and the 
informed consent obtained from these patients only allows their 
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data to be deposited as “Controlled Access” data behind a dbGap 
firewall. Users with appropriate IRB and institutional protec-
tions can access the data. Data from targeted exon sequencing 
from primary T-ALL patient samples is available in the dbGap 
controlled-access database, study ID phs001513.
RNA-seq of T-ALL patient samples
RNA was extracted from T-ALL patient samples using the AllPrep 
DNA/RNA Mini kit (Qiagen) according to the manufacturer’s in-
structions. RNA samples were then treated with Ambion Turbo 
DNase (Thermo Fisher Scientific), and DNA contamination was 
confirmed to be <10% for all samples. RNA quantity was deter-
mined using the Qubit RNA Assay kit (Thermo Fisher Scientific), 
and RNA quality was determined on an Agilent Bioanalyzer using 
the RNA Pico kit (Agilent). Using the NEBNext Ultra RNA Library 
Prep kit for Illumina (New England Biolabs), 50–100 ng of total 
RNA was converted into a DNA library following the manufactur-
er’s protocol. Following library construction, DNA libraries were 
then put through quality control. Library quantity was deter-
mined using the Qubit High Sensitivity DNA kit (Thermo Fisher 
Scientific), and library size was determined using the Bioana-
lyzer High Sensitivity Chip kit (Agilent). Finally, libraries were 
put through qRT-PCR using the Universal Library Quantification 
kit for Illumina (Kapa Biosystems) and run on the 7900HT Fast 
Real-Time PCR machine (Applied Biosystems). Libraries pass-
ing quality control were diluted to 2 nM using sterile water and 
then sequenced on the HiSeq 2000 (Illumina) at a final concen-
tration of 12 pM on a single-read flowcell with 50 sequencing 
cycles, following all manufacturer protocols. Alignments were 
performed with STAR aligner (version 2.3.1z4) against the hg19 
w ERCC92 genome (ftp:// ftp .ensembl .org/ pub/ release -75/ fasta/ 
homo _sapiens/ dna/ ). Cufflinks package was used to generate 
fragments per kilobase of transcript per million mapped reads 
values. These data are from primary patient samples collected 
before the 2015 update of the NIH Genomic Data Sharing policy, 
and the informed consent obtained from these patients only al-
lows their data to be deposited as “Controlled Access” data behind 
a dbGap firewall. Users with appropriate IRB and institutional 
protections can access the data. Data from RNA-seq from primary 
T-ALL patient samples is available in the dbGap controlled-access 
database, study ID phs001513.
Microarray-based CGH analysis of T-ALL patient samples
T-ALL patient samples were profiled for DNA copy number anal-
ysis on SurePrint G3 Human 4×180K CGH Microarrays. Patient 
and control gDNAs were labeled with Cy3 and Cy5 dyes (Perki-
nElmer), and hybridization was performed according to the 
manufacturer’s instructions (Agilent Technologies), followed 
by data analysis using the arrayCGHbase tool (Menten et al., 
2005). Segmentation was performed with the BioConductor 
DNAcopy package, as previously described. Log2 copy number 
ratio for heterozygous deletion was defined as −0.5 to −1.5 (cor-
responding to 35–70% of normal copy number), and log2 copy 
number ratio for homozygous deletion was defined as less than 
−1.5 (corresponding to <35% of normal copy number). Array 
CGH data are available in the NCBI Gene Expression Omni-
bus as GSE96624.
Cell lines and cell culture
Cell lines were obtained from ATCC or DSMZ, as follows: CCRF-
CEM, ATCC cat no. CCL-119; DND41, DSMZ cat no. ACC-525; 
PF382, DSMZ cat no. ACC-38; MOLT4, ATCC cat no. CRL-1582; 
RPMI 8402, DSMZ cat no. ACC-290; Jurkat, ATCC cat no. TIB-
152; and 293T, ATCC cat no. CRL-11268. Cell lines were cultured 
in DMEM or RPMI 1640 (Thermo Fisher Scientific) with 10% FBS 
(Sigma-Aldrich) or tetracycline system–approved FBS (Clon-
tech) and 1% penicillin/streptomycin (Thermo Fisher Scientific) 
at 37°C and 5% CO2. Cell line identities were validated using 
short tandem repeats profiling at the DFCI Institute Molecular 
Diagnostics Laboratory, and mycoplasma contamination was ex-
cluded using the MycoAlert Mycoplasma Detection kit (Lonza), 
most recently in April 2018.
RPMI-8402 is listed in the database of commonly misidenti-
fied cell lines reported by the international cell line authentica-
tion committee. However, short tandem repeat testing verified 
RPMI-8402, and this cell line harbors a deletion immediately 
upstream of TAL1 resulting in its aberrant overexpression, and 
a NOT CH1 mutation that is unique among the T-ALL cell lines 
tested (O’Neil et al., 2007), mutations that are pathognomonic of 
human T-ALL. Thus, we have high confidence that RPMI-8402 is 
a faithful cell line model of human T-ALL.
shRNA and expression plasmids
The following shRNA vectors in pLKO.1 with puromycin re-
sistance were obtained from the RNAi consortium of the 
Broad Institute: shGFP (TRCN000007218); shLuciferase 
(TRCN0000072243); shEZH2 no. 1 (TRCN0000040073); shEZH2 
no. 4 (TRCN0000040076); shEED no. 2 (TRCN0000021205); 
shEED no. 5 (TRCN0000021208); shSUZ12 no. 2 
(TRCN0000038725); shSUZ12 no. 3 (TRCN0000038727); shEZH1 
no. 3 (TRCN0000002441); shTRAP1 no. 4 (TRCN0000244240); 
and shCRIP2 no.3 (TRCN0000243399). For experiments com-
bining shEZH2 knockdown with knockdown of a second gene 
(EZH1, CRIP2, or TRAP1), shEZH2 no. 1 was also cloned into a 
neomycin-resistant pLKO.1 vector generated by the S. Stewart 
laboratory (Washington University, St. Louis, MO) and obtained 
from Addgene (13425).
pInducer20 expression constructs encoding WT or a cata-
lytically impaired triple mutant of EZH2 (F672I/H694A/R732K) 
were previously described (Kim et al., 2015). TRAP1 and EGFP 
protein-coding sequences were amplified in an attB-flanked 
PCR product from plasmid EX-Z0100-Lv105 or EX-LV105-EGFP, 
respectively (Genecopoeia), cloned using the Gateway clonase 
BP into pDONR221, and subsequently cloned into pInducer20 
(44012; Addgene) using the Gateway clonase LR recombina-
tion (Thermo Fisher Scientific). EPB41L1 was obtained from 
pDONR221 EPB41L1 (DNA SU clone ID 43369), and Gateway-cloned 
into destination vector pLenti CMV Puro DEST (w118-1; 17452; 
Addgene). AttB-flanked PCR products of RALB, IGF-1R and dTo-
mato were amplified from Addgene vectors nos. 50989, 11212, 
and 48687 and subsequently Gateway-cloned into pLenti CMV 
Puro DEST. FAM149A, CRIP2, VOPP1, FITM2, TSP AN9, SDC3, and 
MXRA7 coding sequences were synthesized as attB-flanked oli-
gonucleotides by Eurofins Genomics, and Gateway-cloned into 
pLenti CMV Puro DEST. PHL DB1 was produced by Eurofins as 
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multiple GeneStrands with flanking attL sides (5 × 500–1,000 bp) 
and assembled with the Gibson Assembly Cloning kit according 
to protocol; afterward, LR recombination was used to transfer 
PHL DB1 into the pLenti CMV Puro DEST destination vector. All 
destination plasmids were deposited into the Addgene repository 
(nos. 107499–107510).
Lentiviral production, infection, and selection
Lentiviruses were generated by cotransfecting pLKO.1, pIn-
ducer20, or pLenti CMV Puro DEST plasmids of interest to-
gether with packaging vectors psPAX2 and pMD2.G using Fugene 
(Promega). Lentiviral infection was performed by spinoculat-
ing T-ALL cell lines with virus-containing media (1,500 g × 90 
min) in the presence of 8 µg/ml polybrene (Merck Millipore). 
Selection with antibiotics was begun 24 h after infection with 
neomycin (700 µg/ml for a minimum of 5 d; Thermo Fisher Sci-
entific), puromycin (1 µg/ml for a minimum of 48  h; Thermo 
Fisher Scientific), or blasticidin (15 µg/ml for a minimum of 7 
d; Invivogen). After 7 d of selection, shLuc, shEZH2, shEED, or 
shSUZ12 cells were used for BH3 profiling or chemotherapy ex-
posure experiments. Transgene expression in pInducer20-based 
constructs was induced by treatment with 750 ng/µl doxycycline 
(Sigma-Aldrich) for at least 72 h before beginning BH3 profiling 
or chemotherapy exposure experiments. pLenti CMV Puro DEST 
cells were selected for 10 d before BH3 profiling and qRT-PCR 
analysis. CCRF-CEM clone E (EZH2 mutant) and parental Cas9 
control cells were infected with pLenti CMV Puro DEST EGFP or 
tdTomato, respectively, and EGFP or tdTomato positive cells were 
sorted using a Facsaria II (BD Biosciences). Sorting efficiency 
(>99.5%) was confirmed by FACS analysis 48 h after sorting be-
fore starting experiments.
qRT-PCR and primers
RNA was isolated using RNeasy kit (Qiagen), and cDNA was made 
using SuperScript III first-strand cDNA synthesis kit (Thermo 
Fisher Scientific). qRT-PCR was performed using Power SYBR 
green PCR Master Mix (Thermo Fisher Scientific) and 7500 re-
al-time PCR system (Applied Biosystems). Primers used were as 
follows (all 5′–3′): Human Bactin F: CTG GCA CCC AGC ACA ATG; 
Human Bactin R: GCC GAT CCA CAC GGA GTA CT; Human EZH2 
F: TGG AAA GAA CGG AAA TCT TAA ACC; Human EZH2 R: GGA 
TGA CTT GTG TTG GAA AAT CC; Human EZH1 F: GAG TTG GTC GAT 
GCC CTG AAT; Human EZH1 R: AGC ATG TCG CTT TCT CTT TCTT; 
Human EED F: GTG ACG AGA ACA GCA ATC CAG; Human EED R: 
TAT CAG GGC GTT CAG TGT TTG; Human SUZ12 F: AGG CTG ACC 
ACG AGC TTT TC; Human SUZ12 R: GGT GCT ATG AGA TTC CGA 
GTTC; Human TRAP1 F: TTG CAG GCA GGA CGA CTGT; Human 
TRAP1 R: GCT TGG CCG TCA GAC ACC; Human CRIP2 F: CCA AAT 
GCC CCA AGT GCG ACA AG; Human CRIP2 R: CGG GCG TCA GCG TCT 
TGCT; Human BAD F: CCC AGA GTT TGA GCC GAG TG; Human BAD 
R: CCC ATC CCT TCG TCG TCCT; Human BAK1 F: GTT TTC CGC AGC 
TAC GTT TTT; Human BAK1 R: GCA GAG GTA AGG TGA CCA TCTC; 
Human BAX F: CCC GAG AGG TCT TTT TCC GAG; Human BAX R: 
CCA GCC CAT GAT GGT TCT GAT; Human BCL-2 F: GGT GGG GTC 
ATG TGT GTGG; Human BLC-2 R: CGG TTC AGG TAC TAC GTC ATCC; 
Human BCL-B F: GCC AGG TTA CGG CAG ATT CA; Human BCL-B R: 
GAA GGT CAC GAG CGT CACC; Human BID F: ATG GAC CGT AGC ATC 
CCT CC; Human BID R: GTA GGT GCG TAG GTT CTG GT; Human BIM 
F: TAA GTT CTG AGT GTG ACC GAGA; Human BIM R: GCT CTG TCT 
GTA GGG AGG TAGG; Human BMF F: GAG CCA TCT CAG TGT TGG AG; 
Human BMF R: GCC AGC ATT GCC ATA AAA GAG TC; Human BNIP3 
F: CAG GGC TCC TGG GTA GAA CT; Human BNIP3 R: CTA CTC CGT 
CCA GAC TCA TGC; Human BOK F: GTC TTC GCT GCG GAG ATC AT; 
Human BOK R: CAT TCC GAT ATA CGC TGG GAC; Human BCL-W 
F: CGT CCC CGT ATA GAG CTG TG; Human BCL-W R: GGA CAA GTG 
CAG GAG TGG AT; Human BCL-XL F: GAC TGA ATC GGA GAT GGA 
GACC; Human BCL-XL R: GCA GTT CAA ACT CGT CGC CT; Human 
BFL1 F: AGT GCT ACA AAA TGT TGC GTTC; Human BFL1 R: GGC 
AAT TTG CTG TCG TAG AAG TT; Human BIK F: GGA GCT GCT CAT 
ACA GGA GG; Human BIK R: GTG GCT TAC AGA CGC TGCC; Human 
HRK F: CCT TTC AAG CTC TGG GCTC; Human HRK R: CAG GCG GAA 
CTT GTA GGA AC; Human MCL1 F: GTG CCT TTG TGG CTA AAC ACT; 
Human MCL1 R: AGT CCC GTT TTG TCC TTA CGA; Human NOXA 
F: AAG TTT CTG CCG GAA GTT CA; Human NOXA R: GCA AGA ACG 
CTC AAC CGAG; Human PUMA F: GAC CTC AAC GCA CAG TAC GAG; 
Human PUMA R: AGG AGT CCC ATG ATG AGA TTGT; Mouse GAP DH 
F: CGT GGA GTC TAC TGG TGT CTT CAC; Mouse GAP DH R: TTG GCT 
CCA CCC TTC AAG TG; Mouse TRAP1 F: AGC CGA GGA CAA GGA 
GGAG; Mouse TRAP1 R: GCA TCC GTC TGA AGG TGA ATC; Mouse 
CRIP2 F: CCC CAT CGA GGT CCC TGT GGT; Mouse CRIP2 R: ACT 
AGA GGC TTT GCT GGG ACC CT; Mouse Bactin F: GGC TGT ATT CCC 
CTC CAT CG; and Mouse Bactin R: CCA GTT GGT AAC AAT GCC ATGT.
Western blot and antibodies
Cells were lysed in radioimmunoprecipitation assay buffer 
(Merck Millipore) supplemented with cOmplete protease inhib-
itor (Roche) and PhosSTOP phosphatase inhibitor (Roche). 20 µg 
of protein lysate was mixed with Laemmli sample buffer (Bio-
Rad) and β-mercaptoethanol (Sigma-Aldrich) before being run 
on a 4–12% Novex Bis-Tris polyacrylamide gel (Thermo Fisher 
Scientific). Blots were transferred to polyvinylidene fluoride 
membrane (Thermo Fisher Scientific) and blocked with 5% milk 
(Thermo Fisher Scientific) or 5% BSA (New England Biolabs) in 
phosphate-buffered saline with 0.1% Tween (Boston Bioprod-
ucts) and probed with the following antibodies: Total histone H3 
(1:1,000, no. 4499; Cell Signaling Technology), Tri-methyl-his-
tone H3 Lys 27 (1:1,000; no. 07-449; Merck Millipore), EZH2 
(1:1,000; no. 5246; Cell Signaling Technology), SUZ12 (1:1,000; 
no. 3737; Cell Signaling Technology), TRAP1 (1:1,000; no. 612344; 
BD Biosciences), β-tubulin (1:1,000; no. 2128; Cell Signaling Tech-
nology). Secondary detection of horseradish peroxidase–linked 
antibodies (Cell Signaling Technology) with horseradish perox-
idase substrate (Thermo Fisher Scientific) was visualized using 
Amersham Imager 600 (GE Healthcare Life Sciences). All anti-
bodies were validated using the shRNA knockdown or overex-
pression experiments shown in this manuscript.
BH3 profiling of T-ALL cell lines
BH3 profiling of T-ALL cell lines was performed by flow cytom-
etry to assess effects of BIM BH3 peptide or PUMA2A negative 
control on cytochrome c release, as previously described (Bhola 
et al., 2016). 100,000 T-ALL cells were incubated with 1 µM BIM 
or inactive PUMA2A peptide (Tufts University Core Facility, Bos-
ton, MA) in DTEB buffer (135 mM trehalose, 50 mM KCl, 20 µM 
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EDTA, 20  µM EGTA, 5  mM succinate, 0.1% BSA, and 10  mM 
Hepes-KOH; final pH, 7.5) containing 0.002% (wt/vol) digitonin 
(Sigma-Aldrich) for 25 or 30 min, as indicated. Cells were then 
fixed in 2% paraformaldehyde (Alfa Aesar). Cytochrome c was 
then stained using 1:40 anti–cytochrome c antibody conjugated 
to either Alexa Fluor 488 or 647 (nos. 560263 and 558709; BD Bio-
sciences) in cytochrome c–staining buffer (20% FBS, 10% BSA, 1% 
Saponin, and 3 mM Sodium Azide in PBS) overnight at 4°C and 
analyzed on an LSR-II (BD Biosciences).
Assessment of chemotherapy-induced apoptosis
T-ALL cells (10,000 or 40,000 per well) were seeded in 96-well 
plates and incubated with chemotherapeutic agents at the doses 
indicated below for 48 h. Chemotherapy doses were as follows 
unless otherwise indicated: asparaginase, 10 international units/
ml (Sigma-Aldrich); dexamethasone, 10  µM (Sigma-Aldrich); 
vincristine, 1 µM (Selleckchem); doxorubicin, 1 µM (Sigma-Al-
drich); etoposide, 10  µM (Sigma-Aldrich); cytarabine, 10  µM 
(Selleckchem); nelarabine, 10 µM (Sigma-Aldrich); 6-mercapto-
purine, 10 µM (Abcam); and methotrexate, 10 µM (Selleckchem). 
Annexin V and propidium iodide staining were assessed using 
the Apoptosis Detection kit II (BD Biosciences), and caspase 3/7 
activity was assessed using the Caspase Glo 3/7 Assay (Promega) 
according to the manufacturer’s instructions.
Cell cycle
Vybrant DyeCycle violet stain was used to determine cell cycle 
according to manufacturer’s protocol (Life Technologies and 
Thermo Fisher Scientific). 500,000 cells were incubated with 
500 µl RPMI + 1 µl Dyecycle for 90 min at 37°C, and fluorescence 
was measured using a LSR-II Flow Cytometer (BD Biosciences).
Mice
Ezh2 and Eed conditional knockout mice were previously de-
scribed (Shen et al., 2008; Neff et al., 2012), and crossed to Mx1: 
Cre transgenic mice (stock no. 003556; The Jackson Labora-
tory), all maintained in the C57BL/6 background (The Jackson 
Laboratory). All mice used for experiments in this study were 
generated from crosses of siblings that were Ezh2 or Eed fl/wt, 
crossed to animals that were either fl/wt or wt/wt. In all exper-
iments, only one of the parents also carried a single copy of the 
Mx1: Cre transgene.
Ezh2 and Eed genotyping and assessment for Cre-induced 
deletion were performed with 3-primer PCR using the following 
primers (all 5′–3′): Ezh2-F: CCC ATG TTT AAG GGC ATA GTG ACA TG; 
Ezh2-R: ATG TGC AGG TCA GTC AGC AAC TTC AG: Ezh2-onelox: TCG 
AGG GAC CTA ATA ACT TCG TAT AGCA; Eed-F: CTA CGG GCA GGA 
GGA AGAG; Eed-R: GGG GGA GAG GGA GTT GTC; Eed-onelox: CCA 
CAT AGG CTC ATA GAA TTG; MXCre-F: GCG GTC TGG CAG TAA AAA 
CTA TC; MXCre-R: GTG AAA CAG CAT TGC TGT CAC TT.
No statistical methods were used to predetermine sample size. 
6 Ezh2 wt/wt (5 males and 1 female) mice were compared with 5 
Ezh2 fl/wt (1 male and 4 females) siblings and 9 Eed wt/wt mice 
(3 males and 6 females) to 12 Eed wt/fl (7 male and 5 female) sib-
lings. Animals were excluded from analysis only if PCR analysis 
revealed ineffective deletion of Ezh2 or Eed by pIpC treatment, 
which was a preestablished criterion, and when this occurred, the 
entire cohort of mice from that experimental batch was excluded 
from analysis. No randomization nor blinding was done. Mice 
were handled in strict accordance with Good Animal Practice as 
defined by the Office of Laboratory Animal Welfare. All animal 
work was done with Boston Children’s Hospital Institutional Ani-
mal Care and Use Committee approval (protocol no. 15-10-3058R).
Engraftment of human cell lines for in vivo drug treatment 
studies were performed into NRG NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/
SzJ immunodeficient mice (stock no. 007799; Jackson Laboratory).
Staining, sorting, BH3 profiling, and qRT-PCR of 
mouse thymocytes
Ezh2 or Eed fl/wt or wt/wt mice that also expressed the Mx1: Cre 
transgene were treated beginning at 6 wk of age with five doses 
of 15 µg/g pIpC (Sigma-Aldrich) given every other day to excise 
Ezh2 or Eed. Mice were sacrificed 4 wk after the last pIpC dose 
and the thymus was isolated. Mouse thymocytes were dissoci-
ated through a 40-µm mesh filter, and red blood cells were lysed 
using the BD Biosciences Red Blood Cell Lysis reagent. Isolated 
thymocytes were stained for the following markers of T cell de-
velopment using the following antibodies from BD Biosciences: 
CD3e-PerCP (1:100; no. 553067), CD4-BV650 (1:400; no. 563747), 
CD117-PE-Cy7 (1:200, no. 558163), CD44-APC (1:200; no. 559250), 
CD8a-APC-Cy7 (1:400; no. 557654), CD25-BV421 (1:200; no. 
562606), and CD28-PE (1:200; no. 553297). Cells were also stained 
for CD19-Biotin (1:400; no. 553784), Ter-119-Biotin (1:400; no. 
553672), NK1.1-Biotin (1:400; no. 553163), and Gr1-Biotin (1:400, 
no. 553125; all from BD Biosciences) for negative selection using 
a Streptavidin-V500 secondary antibody (1:100; no. 561419; BD).
BH3 profiling was then performed on these stained cells based 
on flow cytometry for cytochrome c release, as previously de-
scribed (Bhola et al., 2016). In brief, thymocytes were incubated 
with 1 µM active hBIM peptide or PUMA2A inactive control for 30 
min in DTEB buffer (135 mM trehalose, 50 mM KCl, 20 µM EDTA, 
20 µM EGTA, 5 mM succinate, 0.1% BSA, and 10 mM Hepes-KOH; 
final pH, 7.5) containing 0.002% (wt/vol) digitonin (Sigma-Al-
drich) and fixed in 2% paraformaldehyde (Alfa Aesar). Cytochrome 
c was then stained using anti–cytochrome c antibody Alexa Fluor 
488 (1:40; no. 560263; BD Falcon) in cytochrome c staining buffer 
(20% FBS, 10% BSA, 1% Saponin, and 3 mM Sodium Azide in PBS) 
overnight at 4°C. Samples were analyzed on an LSR-II instrument 
(BD Biosciences). Results are reported only for thymocyte subsets 
in which >250 events were consistently captured.
For qRT-PCR purposes, stained thymocytes were sorted for 
the indicated populations using a Facsaria II (BD Biosciences). 
RNA isolation, cDNA synthesis and qRT-PCR analysis was per-
formed as described in quantitative reverse transciptase PCR and 
primers section.
Generation of EZH2 mutant CCRF-CEM clones 
using CRI SPR-Cas9
A gRNA targeting exon 5 of EZH2 (NM_004456) was generated by 
annealing the oligonucleotides (F: 5′-CAC CGT TAT GAT GGG AAA 
GTA CACG-3′; R: 5′-CAA TAC TAC CCT TTC ATG TGC CAAA-3′) and 
cloning into pHK09-combomod-Puro (provided by D. Bauer Lab, 
Boston, USA), which is a modified version of LentiGuide-Puro 
(52963; Addgene) harboring sequence modifications to optimize 
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gRNA stability. In brief, 1 µl of 100 µm forward and reverse oligo 
was mixed with 1 µl 10× T4 DNA Ligation Buffer (New England 
Biolabs), 6.5 µl ddH2O, 0.5 µl T4 PNK (New England Biolabs), and 
annealed for 30 min at 37°C and 5 min 95°C. 1 µl phosphoannealed 
oligo 1:500 was then ligated into 1 µl of BsmBI-digested lentiviral 
pHK09-puro plasmid using 1 µl Quick Ligase (New England Bio-
labs), 5 µl 2× Quick Ligase buffer (New England Biolabs) and 2 µl 
ddH2O for 5 min at room temperature.
Lentivirus of pHK09-combomod-puro and Lenti-Cas9-Blast 
(52962; Addgene) was produced as described in the Lentiviral 
production section below. CCRF-CEM cells were infected with 
Lenti-Cas9-Blast and selected in blasticidin for 7 d, whereafter 
cells were infected with pHK09-puro and selected with puro-
mycin for at least 48 h. Single-cell clones were made and gRNA 
cutting frequency was determined by PCR amplification of the 
gRNA target locus (F: 5′-TTA GGT GGA AGA TGA AAC TGT TTTA-3′; 
R: 5′-TCA TGC CCT ATA TGC TTC ATA AA-3′), followed by next-gen-
eration sequencing at the MGH CCIB DNA Core facility. Cutting 
efficiency was assessed using CrispRVariantsLite v1.1 (Lindsay 
et al., 2016). The EZH2 mutant clone described was then infected 
with pInducer20 EZH2 WT or EZH2 mutant, selected in neomy-
cin for 5 d, and used for BH3-profiling and Western blot.
Pooled CRI SPR/Cas9 gRNA transduction and chemotherapy 
treatment of CCRF-CEM cells
A pooled gRNA library with four unique gRNAs targeting the cat-
alytic SET domain of EZH2, and four unique gRNAs targeting the 
safe-harbor AAVS1 locus located in intron 1 of the PPP1R12C gene, 
were designed as described (Sanjana et al., 2014), and cloned into 
the pHKO9-combomod-puro lentiviral vector as described above. 
gRNA target sequences were as follows: EZH2-SET_a, 5′-ATT GCT 
GGC ACC ATC TGA CG-3′; EZH2-SET_b, 5′-AAG ATG AAG CTG ACA 
GAA GA-3′; EZH2-SET_c, 5′-GTG GTG GAT GCA ACC CGC AA-3′; 
EZH2-SET_d, 5′-AAA ACA GCT CTT CGC CAG TC-3′; AAVS1_a, 5′-
AGC GGC TCC AAT TCG GAA GT-3′; AAVS1_b, 5′-GCT CAA AGT GGT 
CCG GAC TC-3′; AAVS1_c, 5′-GAG AGG TGA CCC GAA TCC AC-3′; and 
AAVS1_d, 5′-AGT TCT TAG GGT ACC CCA CG-3′.
Lentivirus was produced by cotransfecting equal amounts 
of each of these gRNAs together with the psPAX2 and pMD2.G 
vectors as described below. Virus was concentrated using 
the Beckmann XL-90 ultracentrifuge (Beckman Coulter) at 
100,000  g (24,000 rpm) for 2  h at 4°C. Viral titers were de-
termined using AlamarBlue staining, as described (https:// 
portals .broadinstitute .org/ gpp/ public/ resources/ protocols). 
CCRF-CEM cells expressing Cas9 protein were plated in 96-well 
format (40,000 cells per well in 100 l RPMI medium), and in-
fected with 12,000 infectious units of lentivirus encoding this 
pool of gRNAs, for a multiplicity of infection of 0.3. Infected 
cells were selected 48  h post-infection with puromycin at 1 
µg/ml for 7 d. Infected cells were treated with vehicle (RPMI 
medium) or 30 nM of vincristine for 48  h in 24-well format 
(400,000 cell per well in 1 ml RPMI medium), and then trans-
ferred into fresh media without vincristine. Cells were har-
vested 14 d after start of vincristine treatment, and genomic 
DNA was extracted using DNeasy Blood and Tissue kit (Qiagen). 
gRNA sequences were PCR-amplified using pHKO9 sequencing 
primers (pHKO9: F, 5′-TCT TGT GGA AAG GAC GAA ACA CCG-3′; 
pHKO9, R, 5′-TCT ACT ATT CTT TCC CCT GCA CTGT-3′), PCR-pu-
rified using the QIAquick PCR purification kit (Qiagen), se-
quenced using CRI SPR sequencing at the MGH CCIB DNA Core 
facility described above, and gRNA cutting efficiency was calcu-
lated using an in-house python script.
Chemotherapy treatment of CCRF-CEM EZH2 mutant clone E 
and parental Cas9 controls
Clone E (EZH2 mutant) and the parental Cas9 control were plated 
and split every other day at a density of 0.5 million/ml. Cells were 
treated with vincristine (50 nM) or vehicle (DMSO) for 48 h; af-
terward, they were released into nonchemotherapy-containing 
growth media (RPMI 1640 with 10% FBS), and viable cell counts 
were assessed by trypan blue exclusion using a Countess II Auto-
mated Cell Counter (Thermo Fisher Scientific) according to the 
manufacturer’s instructions.
To assess relative fitness of EZH2 mutant clone E cells versus 
parental Cas9 controls upon chemotherapy treatment in co-cul-
ture experiments, EGFP-transduced EZH2 mutant clone E cells, 
and tdTomato-transduced Parental Cas9 cells were mixed at a 
1:1 ratio and treated with vincristine (50 nM), etoposide (5 µM), 
cytarabine (10  µM), doxorubicin (100 nM), and methotrexate 
(1 µM) for 48 h, and then released into standard growth media 
for 4 d. The percent EGFP and dTomato cells was assessed with 
FACS analysis using the LSR II flow cytometer (BD Biosciences), 
and data were analyzed using FlowJo version 10.4.2.
To assess relative fitness of EZH2 mutant clone E cells versus 
parental Cas9 controls upon in vivo chemotherapy treatment, 
EGFP-transduced EZH2 mutant clone E cells and tdTomato-trans-
duced Parental Cas9 cells were mixed at a 1:1 ratio and injected by 
tail vein injection (0.5 million cells/mouse) into 8-wk-old NRG 
mice (stock no. 007799; The Jackson Laboratory). Mice were 
treated with irradiation (450 cGy) 3 h before transplantation. 
Mice (n = 5 per group) were treated with either vehicle (0.9% 
sodium chloride solution) or vincristine 2 mg/kg via intraperi-
toneal injection. Mice were monitored daily and supportive care 
(hydrogel, bacon bites, and 300 µl normal saline solution via sub-
cutaneous injection) were administered daily for the duration of 
the experiment. Mice were sacrificed at day 19 after leukemia in-
jection, the spleen was isolated and dissociated through a 40-µM 
mesh filter, and red blood cells were lysed using Red Blood Cell 
Lysis reagent (BD Biosciences). Mice spleen cells were analyzed 
by FACS analysis as described above.
RNA-seq of T-ALL cell lines after PRC2 depletion
RNA was isolated from an equal number of CCRF-CEM cells 8 d 
after infection with shGFP, shLuciferase, shEZH2 no. 1, shEZH2 
no. 4, shEED no. 2, shEED no. 5, shSUZ12 no. 2, or shSUZ12 no. 
3. RNA was extracted using RNeasy kit (Qiagen). Samples were 
treated with Ambion Turbo DNase (Thermo Fisher Scientific) to 
yield DNA contamination below 10%. 3 μl of 1:10 ERCC spike-in 
controls (Ambion; Thermo Fisher Scientific) were added to 5,000 
ng of RNA. Quality of RNA was assessed using the Agilent 2100 
Bioanalyzer. Library preparation and sequencing were per-
formed as for the T-ALL patient samples, as described above.
RNA sequences were aligned with STAR aligner (version 
2.3.1z4) against the hg19 w ERCC92 genome (ftp:// ftp .ensembl 
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.org/ pub/ release -75/ fasta/ homo _sapiens/ dna/ ). The RUV-Seq 
package was used to normalize to spike-in controls. Feature-
Counts software was used to produce integer counts (raw read 
counts) for all genes in the supplied genome annotation file, 
which were then normalized using DESeq package, and these 
normalized read counts are shown in Table S7. Two control shR-
NAs (shLuciferase; shGFP) were compared with six PRC2 shRNA 
(shEZH2 no. 1, shEZH2 no. 4, shEED no. 2, shEED no. 5, shSUZ12 
no. 2, and shSUZ12 no. 3), using DESeq2 analysis. Genes that 
were significantly up-regulated following PRC2 depletion were 
defined based on log2 fold-change >0.45 and nominal P value 
<0.02, as calculated by DESeq2 analysis, and the heat map was 
generated using GENE-E. RNA-seq of T-ALL cells following de-
pletion of PRC2 genes is available as NCBI GEO entry GSE95648.
ChIP-seq
Chromatin immunoprecipitation-sequencing was performed 
as described (Knoechel et al., 2014). In brief, CCRF-CEM cells 
transduced with shRNA-targeting control (Luciferase) or EZH2 
were cross-linked using formaldehyde, and sonication was per-
formed to fragment chromatin to 200–700-bp size range using a 
Covaris E220 Focused-ultrasonicator. Immunoprecipitation was 
then performed on five million cells with anti-H3K4me3 anti-
body (no. 39155; Active Motif), which was validated as described 
(Knoechel et al., 2014). Protein A/G dynabeads were used to pull 
down antibody-bound chromatin, followed by washing and elu-
tion. Cross-linking was reversed with proteinase K treatment, 
and DNA was cleaned up using Solid Phase Reversible Immobili-
zation beads (Beckman Coulter). ChIP DNA was quantified using 
the Qubit system (Invitrogen). Sequencing libraries for ChIP-seq 
were prepared according to Illumina’s instructions. ChIP DNA 
and input were sequenced with the Illumina NextSeq 500 plat-
fom. ChIP-seq reads were aligned to the reference genome (hg19) 
using BWA (version 0.7.13; Li and Durbin, 2009) with default 
parameters and duplicated reads were filtered out with Picard. 
Reads with <20 bases of mapping quality were removed from 
the alignment. ChIP peaks for H3K27me3 were called by Homer 
(Heinz et al., 2010) using default parameters requiring putative 
peak to have threefold more normalized tags in the ChIP exper-
iment than the input and a cumulative poisson P value thresh-
old of 0.001. Putative peaks that were identified in regions of 
genomic duplication or repeat elements were filtered out. Note 
that there were no significant peaks identified in CCRF-CEM cells 
transduced with shEZH2, indicating that EZH2 is the primary 
H3K27me3 “writer” in these cells. ChIP-seq peaks were called 
significant if the maximum peak intensity was > 0.7, a cutoff 
verified by manual examination of peaks using Integrative Ge-
nomics Viewer version 2.3.93. ChIP-seq of T-ALL cells following 
depletion of EZH2 is available as NCBI GEO entry GSE112147.
Gamitrinib single agent and synergy testing
CCRF-CEM cells were infected with the indicated shRNAs, and 
puromycin selection was begun 24 h after infection. After 8 d 
of puromycin selection, treatment with vehicle (DMSO) or the 
indicated doses of gamitrinib was performed for 48  h, after 
which cell viability was assessed using CellTiter-Glo (Promega). 
Synergy of gamitrinib in combination with dexamethasone 
or doxorubicin was tested in CCRF-CEM cells infected with 
shEZH2 no. 1 selected for 8 d in puromycin. In brief, 5,000 cells 
were plated in 384-well format using a Biotek MicroFlo Select 
Dispenser. Drug concentration combinations, across a serial 
twofold dilution range around previously determined IC50 con-
centrations, were plated in quadruplicate onto the cells using a 
Bravo Automated Liquid Handling Platform (Agilent). Viability 
was then assessed after 48  h of treatment using CellTiter-Glo 
(Promega). The Chou-Talalay method was used to calculate 
combination indexes of the fractional inhibition using Com-
puSyn software. Fractional inhibition was defined as 1, relative 
cell viability.
GSK126 treatment of patient-derived xenografts
Human T-ALL patient-derived xenografts were engrafted into 
immunodeficient mice as described (Townsend et al., 2016). Pa-
tient-derived cells were cultured in the presence of recombinant 
human cytokines stem cell factor (50 ng/ml), Flt3-liter (20 ng/
ml) and IL-7 (10 ng/ml; R&D Systems) at 37° under 5% CO2, as 
described (Reynolds et al., 2014; Burns et al., 2018). Cells were 
treated with vehicle or 1 µM GSK126 (Cayman Chemical) for 6 d, 
and qRT-PCR was performed as described above.
Statistical analyses
Overall survival was calculated from the time of registration to 
the time of death censored at the last known follow up. Event-
free survival was calculated from the time of registration to re-
lapse or death and was censored at the last known follow up. 
Induction failures were included as events at time zero. The log-
rank test was used to test for differences in survival between 
groups, and the method of Kaplan and Meier was used to con-
struct survival curves.
Significance of RNA-seq read counts, which are not nor-
mally distributed, was performed using DESeq analysis, which 
accounts for the negative binomial distribution of RNA-seq data, 
as described above. For two-group comparisons of continuous 
measures, a two-tailed Welch unequal variances t test was used. 
For three-group comparisons of continuous measures, ANO VA 
was performed and a Tukey adjustment for multiple compar-
isons was used. For analysis of two effects, a two-way ANO VA 
model was constructed and, unless indicated, included an in-
teraction term between the two effects. Post hoc adjustment for 
multiple comparisons for two-way ANO VA included either a 
Tukey or Sidak adjustment depending on the pairwise compar-
isons of interest.
Data shown as bar graphs represent the mean and standard 
error of the mean of a minimum of three biological replicates. 
For experiments performed in duplicate, results from each rep-
licate are shown as individual data points. All P values reported 
are two-sided except for the one-sided analysis of the association 
of TRAP1 overexpression with inferior survival in Fig. 6 I, as indi-
cated, due to the hypothesized direction of the difference before 
testing. P values were considered significant if <0.05.
Online supplemental material
Fig. S1 shows the lack of association of mitochondrial apoptosis 
resistance in primary T-ALL patient samples with RNA expres-
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sion of BCL2 family genes or with oncogenic mutations previ-
ously associated with treatment response. Fig. S2 shows that 
shRNA depletion of EZH1 does not reverse chemotherapy resis-
tance induction by shRNA knockdown of EZH2. Fig. S3 shows 
that shRNA depletion of PRC2 subunits has no consistent effect 
on mRNA expression of any known pro- or antiapoptotic BCL2 
family genes. Fig. S4 shows effects of TRAP1- and EZH2-target-
ing shRNAs on expression of their target mRNAs and that shRNA 
depletion of TRAP1 reverses the ability of EZH2 depletion to in-
duce chemotherapy resistance. Fig. S5 shows effects of CRIP2 and 
EZH2-targeting shRNAs on expression of their target mRNAs, 
and that shRNA depletion of CRIP1 reverses the ability of EZH2 
depletion to induce chemotherapy resistance. Table S1 shows 
a summary of clinical features and genotyping of the primary 
T-ALL patient samples analyzed. Table S2 shows association of 
clinical features with mitochondrial apoptotic priming. Table S3 
shows the genes whose protein-coding exons were sequenced by 
targeted exome sequencing. Table S4 shows results of targeted 
exome sequencing. Table S5 shows resuls of array CGH analysis. 
Table S6 shows results of RNA-seq of primary T-ALL patient sam-
ples. Table S7 shows the genotype of EZH2-mutant CCRF-CEM 
clone E cells. Table S8 shows RNA-seq of CCRF-CEM cells trans-
duced with control or PRC2-targeting shRNAs. Table S9 shows 
result of H3K27me3 ChIP-seq in CCRF-CEM cells.
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